ALBI Grade is a Determinant of Lenvatinib Pharmacokinetics, Efficacy, and Toxicities in Japanese Patients with Hepatocellular Carcinoma
Clinical Pharmacokinetics · 2026-08 · 65 (8) · 1229-1241
DOI: 10.1007/s40262-026-01662-0 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Clinical Pharmacokinetics, online erschienen am 23.06.2026. Verfasst von Kosuke Suzuki und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hospital Pharmaceutics, Showa Medical University School of Pharmacy, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan. Hauptthemen laut MEDLINE: Antineoplastic Agents, Bilirubin, Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Society for the Promotion of Science London, SHOWA Medical University.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Hospital Pharmaceutics, Showa Medical University School of Pharmacy, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan.
- Division of Gastroenterology, Department of Medicine, Showa Medical University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan.
- Department of Cancer Genome and Pharmacotherapy, Showa Medical University Graduate School of Pharmacy, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan.
- Division of Cancer Genome and Pharmacotherapy, Department of Clinical Pharmacy, Showa Medical University School of Pharmacy, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan.
- Laboratory of Molecular Pharmacotherapeutics, Faculty of Pharmacy, Kanazawa University, Kakuma-machi, Kanazawa, 920-1192, Japan.
- Department of Cancer Genome and Pharmacotherapy, Showa Medical University Graduate School of Pharmacy, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan. k.fujita@med.showa-u.ac.jp.
Förderung
- Japan Society for the Promotion of Science London
- SHOWA Medical University
Zitieren
APA
Suzuki, K., Otoyama, Y., Matsumoto, N., Masuo, Y., Nakajima, Y., Sugiura, I., Fuji, T., Nomura, E., Ichikawa, Y., Shimozuma, Y., Uchikoshi, M., Hayano, M., Hanano, M., Murase, R., Mitomori, C., Oka, K., Sakaki, M., Kato, Y., Yoshida, H., & Fujita, K. I. (2026). ALBI Grade is a Determinant of Lenvatinib Pharmacokinetics, Efficacy, and Toxicities in Japanese Patients with Hepatocellular Carcinoma. Clinical Pharmacokinetics, 65(8), 1229-1241. https://doi.org/10.1007/s40262-026-01662-0
Vancouver
Suzuki K, Otoyama Y, Matsumoto N, Masuo Y, Nakajima Y, Sugiura I, et al. ALBI Grade is a Determinant of Lenvatinib Pharmacokinetics, Efficacy, and Toxicities in Japanese Patients with Hepatocellular Carcinoma. Clinical Pharmacokinetics. 2026;65(8):1229-1241. doi:10.1007/s40262-026-01662-0
BibTeX
@article{Suzuki2026,
author = {Suzuki, Kosuke and Otoyama, Yumi and Matsumoto, Natsumi and Masuo, Yusuke and Nakajima, Yoko and Sugiura, Ikuya and Fuji, Takahiro and Nomura, Erika and Ichikawa, Yuki and Shimozuma, Yuu and Uchikoshi, Manabu and Hayano, Momoka and Hanano, Mayuko and Murase, Remi and Mitomori, Chika and Oka, Kiyoshi and Sakaki, Masashi and Kato, Yukio and Yoshida, Hitoshi and Fujita, Ken-Ichi},
title = {ALBI Grade is a Determinant of Lenvatinib Pharmacokinetics, Efficacy, and Toxicities in Japanese Patients with Hepatocellular Carcinoma},
journal = {Clinical Pharmacokinetics},
year = {2026},
volume = {65},
number = {8},
pages = {1229--1241},
doi = {10.1007/s40262-026-01662-0}
}
EUVIMED